Trials / Completed
CompletedNCT00609505
Telemedicine vs. Face-to-Face Cancer Genetic Counseling
Telemedicine vs. Face-to-Face Cancer Genetic Counseling in Rural Oncology Clinics
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 130 (actual)
- Sponsor
- Duke University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
Cancer genetic counseling (CGC) has been found to have "substantial" benefits for individuals with breast cancer and their family members; it has been deemed by multiple organizations as "standard of care" for women with breast cancer and their relatives. Unfortunately, there is a disparity in access to CGC, especially among women who live in rural and underserved areas. In North Carolina, only two cancer genetic counselors practice in rural clinics - each only for a few days per month. Therefore, in an effort to make CGC more widely available in a timely manner, we propose to test provision of counseling through telemedicine (TM), in which a patient and health care provider communicate with each other using videoconferencing. In 4 rural oncology clinics, we will implement low-cost TM and compare satisfaction and cost-effectiveness between groups of women designated to have their CGC session by TM or FTF. We'll use a validated measure to assess satisfaction by a phone survey one week after the CGC appointment; cost-effectiveness will be measured at project's end by calculating length of wait time for appointment and costs of equipment, labor, and mileage. Study hypothesis: TM is as satisfactory as FTF counseling and is a more cost-effective way to provide this beneficial service.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Telemedicine | Telemedicine genetic counseling |
| OTHER | Face-to-Face | Face-to-face genetic counseling |
Timeline
- Start date
- 2008-08-01
- Primary completion
- 2011-03-01
- Completion
- 2011-04-01
- First posted
- 2008-02-07
- Last updated
- 2012-02-22
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00609505. Inclusion in this directory is not an endorsement.